Ono Pharmaceutical (OPHLF) Stock Price, News & Analysis

Company Overview

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Key Stats

• Today's Range: $10.95 to $10.95
• 50-Day Range: $9.33 to $11.21
• 52-Week Range: $9.20 to $16.05
• Volume: 5 shs
• Average Volume: 1,170 shs
• Market Capitalization: $5.14 billion
• P/E Ratio: 17.65
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OPHLF Stock Analysis - Frequently Asked Questions

How have OPHLF shares performed this year?

Ono Pharmaceutical's stock was trading at $9.60 at the beginning of 2025. Since then, OPHLF shares have increased by 14.0% and is now trading at $10.9450.

How were Ono Pharmaceutical's earnings last quarter?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) released its quarterly earnings data on Monday, August, 4th. The company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.34 by $0.08. The business earned $886.27 million during the quarter, compared to the consensus estimate of $827.29 million. Ono Pharmaceutical had a trailing twelve-month return on equity of 5.49% and a net margin of 8.75%.

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/04/2025
• Today: 8/14/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:OPHLF
• CIK: 940821
• Web: www.ono.co.jp
• Phone: (166) 263-5670
• Fax: 816-6263-2950
• Employees: 3,853
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.62
• Trailing P/E Ratio: 17.65
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $330.31 million
• Net Margins: 8.75%
• Pretax Margin: 12.19%
• Return on Equity: 5.49%
• Return on Assets: 4.12%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 3.07
• Quick Ratio: 2.56

Sales & Book Value

• Annual Sales: $3.20 billion
• Price / Sales: 1.61
• Cash Flow: $1.08 per share
• Price / Cash Flow: 10.16
• Book Value: $11.07 per share
• Price / Book: 0.99

Miscellaneous

• Outstanding Shares: 469,710,000
• Free Float: N/A
• Market Cap: $5.14 billion
• Optionable: Not Optionable
• Beta: 0.51